EVOLUS INC
EOLSNASDAQ🏆 #2872 by market capEarnings Nov 4 · PostUS Equity
$7.51▼ $0.14 (−1.77%)
Pre-market · at closeTrack EOLS
Get earnings, price moves & breaking news on Telegram
24h▼ 1.8%
7d▲ 7.2%
14d▲ 5.7%
30d▼ 6.2%
ytd▲ 12.7%
1y▲ 12.0%
🏦Market Cap
$496M
Small Cap
📈Revenue Growth (YoY)
13.9%
Healthy
📊Gross Margin
66.7%
High
💵FCF Margin
3.4%
Moderate
⚖️P/S Ratio
1.6x
Cheap
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $7.39 – $7.79
- 52-Week Range
- $3.86 – $9.31
- Volume (shares)
- 43,348
- Avg Volume (shares)
- —
- Shares Outstanding
- 66.0M
- Next Earnings
- 2026-11-04
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- 1.6x
- EPS (TTM)
- $-0.53
- Dividend Yield
- —
EVOLUS INC
EOLSFinancial Trends
Financial history unavailable.
StockOtter · stockotter.spaceAbout EVOLUS INC
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
Overall Score
Insufficient data
—/100
Analyst Ratings
ⓘConsensus
Buy
12 analysts
Strong Buy5
Buy5
Hold2
Sell0
Strong Sell0
Ratings as of Oct 2026
Latest News & Updates
News unavailable.